Wenjun Wu

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

Pin Lu, Shengchun Wang, Carrie A. Franzen et al. · Blood Cancer Journal · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +14

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Mei Ming, Wenjun Wu, Bingqing Xie et al. · Molecular Cancer Therapeutics · 2018 · 47 citations

Medicine, Oncology, Pharmacology +17

Significant association of long non-coding RNAs HOTAIR genetic polymorphisms with cancer recurrence and patient survival in patients with uterine cervical cancer

Shun‐Long Weng, Wenjun Wu, Yi‐Hsuan Hsiao et al. · International Journal of Medical Sciences · 2018 · 43 citations · Full text

Medicine, Genetics, Oncology +15

Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways

Feng-Lang Lin, Jue‐Liang Hsu, Wenjun Wu et al. · European Journal of Pharmacology · 2010 · 40 citations

Life Sciences, Cell Biology, Molecular Biology +16

A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria

Lu Zhang, Hongling Peng, Hao Li et al. · The Lancet Regional Health - Western Pacific · 2023 · 36 citations · Full text

Life Sciences, Internal Medicine, Pathology +12